EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study

Ganesh Bavikatte, Gerard E Francisco iD, Wolfgang H Jost, Alessio Baricich, Esther Duarte, Simon F T Tang, Marc Schwartz, Mariana Nelson, Tiziana Musacchio, Alberto Esquenazi

PM&R · 2024

DOI: 10.1002/pmrj.13195 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PM&R, 2024. Verfasst von Ganesh Bavikatte und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Walton Centre, Liverpool, UK. Hauptthemen laut MEDLINE: Muscle Spasticity, Botulinum Toxins, Type A, Quality of Life, Upper Extremity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Upper and lower limb spasticity is commonly associated with central nervous system disorders including stroke, traumatic brain injury, multiple sclerosis, cerebral palsy, and spinal cord injury, but little is known about the concurrent treatment of upper and lower limb spasticity with botulinum toxins.

Objective

To evaluate onabotulinumtoxinA (onabotA) utilization and to determine if concurrent onabotA treatment of the upper and lower limbs has supported improvements in participants with spasticity.

Design

Sub‐analysis of a 2‐year, international, prospective, observational registry (ASPIRE, NCT01930786).

Setting

International clinic sites (54).

Participants

Adult spasticity participants across etiologies, who received ≥1 concurrent onabotA treatment of the upper and lower limbs during the study.

Intervention

Participants were treated with onabotA at the clinician's discretion. Outcomes Baseline characteristics and outcomes of disability (Disability Assessment Scale [DAS]), pain (Numeric Pain Rating Scale [NPRS]), participant satisfaction, physician satisfaction, and quality of life (QoL; Spasticity Impact Assessment [SIA]) were evaluated. Adverse events were monitored throughout the study.

Results

Of 744 participants enrolled, 730 received ≥1 dose of onabotA; 275 participants received treatment with onabotA in both upper and lower limbs during ≥1 session; 39.3% of participants were naïve to onabotA for spasticity. The mean (SD) total dose per treatment session ranged from 421.2 (195.3) to 499.6 (188.6) U. The most common baseline upper limb presentation was clenched fist ( n = 194, 70.5%); lower limb was equinovarus foot ( n = 219, 66.9%). High physician and participant satisfaction and improvements in pain, disability and QoL were reported after most treatments. Nine participants (3.3%) reported nine treatment‐related adverse events; two participants (0.7%) reported three serious treatment‐related severe adverse events. No new safety signals were identified.

Conclusion

More than a third of enrolled participants received at least one concurrent onabotA treatment of the upper and lower limbs, with reduced pain, disability, and improved QoL after treatment, consistent with the established safety profile of onabotA for the treatment of spasticity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle SpasticityBotulinum Toxins, Type AQuality of LifeUpper ExtremityLower ExtremityNeuromuscular AgentsDisability EvaluationHumansFemaleMaleProspective StudiesMiddle AgedAdultTreatment OutcomePain MeasurementPainAged

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • The Walton Centre, Liverpool, UK.
  • UT Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, Texas, USA.
  • Department of Neurology, University of Freiburg, Freiburg im Breisgau, Germany.
  • Università del Piemonte Orientale, Novara, Italy.
  • Hospital del Mar, Barcelona, Spain.
  • Chang Gung Memorial Hospital, Taoyuan City, Taiwan.

ORCID-Profile: Gerard E Francisco

Förderung

  • AbbVie

Zitieren

APA

Bavikatte, G., Francisco, G. E., Jost, W. H., Baricich, A., Duarte, E., Tang, S. F. T., Schwartz, M., Nelson, M., Musacchio, T., & Esquenazi, A. (2024). Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study. PM&R. https://doi.org/10.1002/pmrj.13195

Vancouver

Bavikatte G, Francisco GE, Jost WH, Baricich A, Duarte E, Tang SFT, et al. Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study. PM&R. 2024. doi:10.1002/pmrj.13195

BibTeX
@article{Bavikatte2024,
  author = {Bavikatte, Ganesh and Francisco, Gerard E and Jost, Wolfgang H and Baricich, Alessio and Duarte, Esther and Tang, Simon F T and Schwartz, Marc and Nelson, Mariana and Musacchio, Tiziana and Esquenazi, Alberto},
  title = {Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study},
  journal = {PM&R},
  year = {2024},
  doi = {10.1002/pmrj.13195}
}
Kostenlos starten →